---
schema_version: "secwatch.filing_event.v1"
accession: "0001070081-24-000021"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:15:03.294254+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PTC Therapeutics Q3 revenue $196.8M, raises FY2024 guidance to $750-800M, multiple FDA submissions

## Summary
- Q3 total revenue $196.8M (vs $196.6M YoY); DMD franchise $124M (Translarna $72M, Emflaza $52M).
- Net loss narrowed to $106.7M from $133M; cash & securities $1.01B.
- FY2024 revenue guidance raised to $750-800M; GAAP R&D+SG&A $740-835M.
- FDA accepted sepiapterin NDA (PKU) with action date July 29, 2025; AADC gene therapy BLA action Nov 13, 2024.
- Plans to submit vatiquinone NDA for Friedreich ataxia in Dec 2024; fast track for PTC518 Huntington's.

## SEC filing metadata
- accession: 0001070081-24-000021
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000107008124000021/0001070081-24-000021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000107008124000021/tmb-20241107x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001070081-24-000021
- JSON: https://secwatch.observer/filing/0001070081-24-000021.json
- Plain text: https://secwatch.observer/filing/0001070081-24-000021.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.